Gft505 Presents an Array of Hope in Nonalcoholic Steatohepatitis (Nash) Therapeutics Market
Submitted by: Submitted by kksingha
Views: 10
Words: 539
Pages: 3
Category: Business and Industry
Date Submitted: 05/22/2016 11:21 PM
Nonalcoholic Steatohepatitis (NASH), also called the ‘silent disease,’ is a kind of fatty liver disease which typically affects people that are obese or diabetic. This disease is more prevalent in the younger generation and causes liver inflammation and/or damage owing to the accumulation of fat within the liver. The exact cause of this disease is still not clear; however, research activities are underway for finding effective treatments to cure this disease.
Transparency Market Research (TMR), a market intelligence company answers some of the chief questions that may prove helpful for companies already established in the Nonalcoholic Steatohepatitis market and also for emerging companies looking to penetrate this market.
Get Free Report Brochure PDF:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691
Q. Why is the treatment of NASH a prime therapeutic need?
Hepatologists have opined that NASH has emerged as a ‘ticking time bomb’ and this is why regulatory authorities such as the EMA and the FDA are supporting the requirements for the discovery of effective treatment options for curing this disease. The therapeutic needs are immense globally owing to the fact that the count of NASH cases is constantly rising, together with the obesity and diabetes epidemic. Within the U.S. alone, the prevalence of NASH is predicted to be more than 12% of the adult population.
In addition, there are a number of predictors and risk factors of NASH such as obesity, Body Mass Index (BMI), insulin sensitivity, hypertension, dyslipidemia, increase in liver enzymes, and obesity. Also, patients having NASH have an increasing risk for peripheral vascular accident or stroke and myocardial infarction.
Q. What factors will support the growth of the market for NASH therapeutics?
The rising rate of diabetes and obesity is a key factor fuelling the growth of the market. In addition, the increase in the number of clinical trials coupled with their...
